Celltrion Pharm Rises 1.32% to 42,100 Won... IBK Investment & Securities: "Subcutaneous Injection Expansion and Biosimilar Policy Are Growth Drivers"
Celltrion Pharm (068760) rose 550 won to trade at 42,100 won on the morning of the 2nd, up 1.32% from the previous day. In the market, the expansion of subcutaneous injection formulations by parent company Celltrion and the Korean government's policy to invigorate domestic biosimilars are being cite

Celltrion Pharm (068760) rose 550 won to trade at 42,100 won on the morning of the 2nd, up 1.32% from the previous day. In the market, the expansion of subcutaneous injection formulations by parent company Celltrion and the Korean government's policy to invigorate domestic biosimilars are being cited as mid- to long-term growth drivers for Celltrion Pharm.
IBK Investment & Securities: "Earnings Guidance and Biosimilar Policy Are Key Variables"
IBK Investment & Securities identified parent company Celltrion's earnings guidance and the Korean government's biosimilar expansion policy as key factors for gauging Celltrion Pharm's growth potential.
In particular, the brokerage analyzed that as Celltrion expands its subcutaneous injection formulations, Celltrion Pharm's business opportunities could also broaden. It explained that if the lineup of subcutaneous injection products, which offer improved dosing convenience compared to existing intravenous formulations, expands, synergies between affiliates could be strengthened in terms of production and supply.
Biosimilar Policy Environment Also a Positive Variable
The policy environment surrounding the domestic biosimilar market was also cited as a positive factor. The assessment is that if the government continues policies focused on activating biosimilar use and strengthening industrial competitiveness, market access for related products could improve.
IBK Investment & Securities said that Celltrion Pharm's growth potential should be viewed not only in terms of its individual businesses but also in light of Celltrion Group's expanding product portfolio and changes in the policy environment. It judged that if the parent company's new product expansion leads to actual production volume increases, earnings levels could gradually rise as well.
Going Forward, Key Factors Are 'Pace of Subcutaneous Injection Expansion and Earnings Reflection'
Going forward, the pace of Celltrion's subcutaneous injection formulation expansion, the specific implementation direction of domestic biosimilar-related policies, and Celltrion Pharm's resulting production and revenue contribution are expected to act as major variables.
Celltrion Pharm is up 550 won, or 1.32%, at 42,100 won today. The market sees, alongside the short-term stock price movement, the extent to which group-level product expansion is actually reflected in Celltrion Pharm's earnings as the key factor that will determine the future direction.
[This article is an informational piece written based on publicly available market information and materials and does not recommend buying, selling, or holding any specific stock. Stock investments may result in loss of principal, and the final investment decision and responsibility rest with the investor. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



